{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:19:36Z","timestamp":1787505576779,"version":"build-2736575974"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40263-025-01178-4","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T06:13:09Z","timestamp":1744611189000},"page":"707-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cenobamate: A Review in Focal-Onset Seizures"],"prefix":"10.1007","volume":"39","author":[{"given":"Tina","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheridan M.","family":"Hoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"issue":"10172","key":"1178_CR1","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","volume":"393","author":"RD Thijs","year":"2019","unstructured":"Thijs RD, Surges R, O\u2019Brien TJ, et al. Epilepsy in adults. Lancet. 2019;393(10172):689\u2013701.","journal-title":"Lancet"},{"issue":"4","key":"1178_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512\u201321.","journal-title":"Epilepsia"},{"issue":"3","key":"1178_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279\u201386.","journal-title":"JAMA Neurol"},{"issue":"1","key":"1178_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40263-022-00979-1","volume":"37","author":"M Janmohamed","year":"2023","unstructured":"Janmohamed M, Hakeem H, Ooi S, et al. Treatment outcomes of newly diagnosed epilepsy: a systematic review and meta-analysis. CNS Drugs. 2023;37(1):13\u201330.","journal-title":"CNS Drugs"},{"key":"1178_CR5","unstructured":"Angelini Pharma S.p.A. Ontozry (cenobamate): EU summary of product characteristics 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ontozry. Accessed 9 Jan 2025."},{"issue":"8","key":"1178_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40267-020-00754-6","volume":"36","author":"SM Hoy","year":"2020","unstructured":"Hoy SM. Cenobamate in focal seizures: a profile of its use. Drugs Ther Perspect. 2020;36(8):327\u201334.","journal-title":"Drugs Ther Perspect."},{"issue":"1","key":"1178_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38\u201348.","journal-title":"Lancet Neurol"},{"issue":"22","key":"1178_CR8","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311\u201322.","journal-title":"Neurology"},{"key":"1178_CR9","unstructured":"European Medicines Agency. Ontozry: EU assessment report. 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ontozry. Accessed 9 Jan 2025."},{"issue":"10","key":"1178_CR10","doi-asserted-by":"publisher","first-page":"e989","DOI":"10.1212\/WNL.0000000000200792","volume":"99","author":"P Klein","year":"2022","unstructured":"Klein P, Aboumatar S, Brandt C, et al. Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022;99(10):e989\u201398.","journal-title":"Neurology"},{"issue":"9","key":"1178_CR11","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/epi.17007","volume":"62","author":"JA French","year":"2021","unstructured":"French JA, Chung SS, Krauss GL, et al. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. Epilepsia. 2021;62(9):2142\u201350.","journal-title":"Epilepsia"},{"issue":"6","key":"1178_CR12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099\u2013108.","journal-title":"Epilepsia"},{"issue":"12","key":"1178_CR13","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1111\/epi.17091","volume":"62","author":"MR Sperling","year":"2021","unstructured":"Sperling MR, Abou-Khalil B, Aboumatar S, et al. Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsia. 2021;62(12):3005\u201315.","journal-title":"Epilepsia"},{"key":"1178_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106940","volume":"183","author":"WE Rosenfeld","year":"2022","unstructured":"Rosenfeld WE, Ferrari L, Kamin M. Efficacy of cenobamate by focal seizure subtypes: post-hoc analysis of a phase 3, multicenter, open-label study. Epilepsy Res. 2022;183: 106940.","journal-title":"Epilepsy Res"},{"key":"1178_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.107014","volume":"186","author":"S Aboumatar","year":"2022","unstructured":"Aboumatar S, Biton V, Wechsler R, et al. Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: adjunctive cenobamate dose and seizure reduction by baseline seizure frequency. Epilepsy Res. 2022;186: 107014.","journal-title":"Epilepsy Res"},{"key":"1178_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106952","volume":"184","author":"B Abou-Khalil","year":"2022","unstructured":"Abou-Khalil B, Aboumatar S, Klein P, et al. Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsy Res. 2022;184: 106952.","journal-title":"Epilepsy Res"},{"issue":"12","key":"1178_CR17","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1111\/epi.17092","volume":"62","author":"WE Rosenfeld","year":"2021","unstructured":"Rosenfeld WE, Abou-Khalil B, Aboumatar S, et al. Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia. 2021;62(12):3016\u201328.","journal-title":"Epilepsia"},{"key":"1178_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.seizure.2022.02.003","volume":"96","author":"C Brandt","year":"2022","unstructured":"Brandt C, S\u00e1nchez-\u00c1lvarez JC, Steinhoff BJ, et al. Efficacy and safety of adjunctive cenobamate: post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications. Seizure. 2022;96:86\u201393.","journal-title":"Seizure."},{"key":"1178_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106592","volume":"172","author":"WE Rosenfeld","year":"2021","unstructured":"Rosenfeld WE, Nisman A, Ferrari L. Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: a post-hoc analysis of a randomized clinical study. Epilepsy Res. 2021;172: 106592.","journal-title":"Epilepsy Res"},{"key":"1178_CR20","unstructured":"Serratosa J, Majkowska-Zwoli\u0144ska B, Alvarez-Baron E, et al. Efficacy of adjunctive cenobamate for patients with different epilepsy aetiologies: results of an open-label study [abstract no. EPR-186]. Eur J Neurol. 2024;31(Suppl 1):e16338."},{"key":"1178_CR21","doi-asserted-by":"crossref","unstructured":"Nisman A, Rosenfeld W, Ferrari L. Long-term efficacy of cenobamate by focal seizure subtype: post-hoc analysis of an open-label extension study [abstract no. 1.31]. In: American Epilepsy Society Annual Meeting. 2023.","DOI":"10.1016\/j.eplepsyres.2022.106940"},{"key":"1178_CR22","unstructured":"Brandt C, Fab\u00f3 D, Milovanovic M, et al. Number of seizure-free days with adjunctive cenobamate: post-hoc analysis of an open-label extension study [abstract no. 1071]. Epilepsia. 2023;64(Suppl 2):58."},{"issue":"1","key":"1178_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/epi.17134","volume":"63","author":"JW Sander","year":"2022","unstructured":"Sander JW, Rosenfeld WE, Halford JJ, et al. Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program. Epilepsia. 2022;63(1):139\u201349.","journal-title":"Epilepsia"},{"issue":"3","key":"1178_CR24","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/epi.17874","volume":"65","author":"Y Novitskaya","year":"2023","unstructured":"Novitskaya Y, Sch\u00fctz E, Metternich B, et al. Add-on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: a prospective observational study. Epilepsia. 2023;65(3):630\u201340.","journal-title":"Epilepsia"},{"issue":"4","key":"1178_CR25","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s40120-024-00634-5","volume":"13","author":"S Lattanzi","year":"2024","unstructured":"Lattanzi S, Ranzato F, Di Bonaventura C, et al. Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: evidence from the first interim analysis of the BLESS study. Neurol Ther. 2024;13(4):1203\u201317.","journal-title":"Neurol Ther."},{"issue":"9","key":"1178_CR26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40263-024-01109-9","volume":"38","author":"Y Winter","year":"2024","unstructured":"Winter Y, Abou Dargham R, Patino Tobon S, et al. Cenobamate as an early adjunctive treatment in drug-resistant focal-onset seizures: an observational cohort study. CNS Drugs. 2024;38(9):733\u201342.","journal-title":"CNS Drugs"},{"issue":"4","key":"1178_CR27","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/epi4.12992","volume":"9","author":"BJ Steinhoff","year":"2024","unstructured":"Steinhoff BJ, Georgiou D, Intravooth T. The cenobamate KORK study: a prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add-on lacosamide, perampanel, and brivaracetam. Epilepsia Open. 2024;9(4):1502\u201314.","journal-title":"Epilepsia Open."},{"issue":"10","key":"1178_CR28","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1111\/epi.18091","volume":"65","author":"R Roberti","year":"2024","unstructured":"Roberti R, Assenza G, Bisulli F, et al. Adjunctive cenobamate in people with focal onset seizures: insights from the Italian Expanded Access Program. Epilepsia. 2024;65(10):2909\u201322.","journal-title":"Epilepsia"},{"key":"1178_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2024.107498","volume":"209","author":"C Saouda","year":"2025","unstructured":"Saouda C, Nofal O, Makke Y, et al. Effectiveness and tolerability of cenobamate: a single center experience. Epilepsy Res. 2025;209: 107498.","journal-title":"Epilepsy Res"},{"issue":"5","key":"1178_CR30","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1111\/epi.17549","volume":"64","author":"J Pe\u00f1a-Ceballos","year":"2023","unstructured":"Pe\u00f1a-Ceballos J, Moloney PB, Munteanu T, et al. Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a \u201creal-world\u201d retrospective study. Epilepsia. 2023;64(5):1225\u201335.","journal-title":"Epilepsia"},{"key":"1178_CR31","doi-asserted-by":"crossref","unstructured":"Pietrafusa N, Falcicchio G, Russo E, et al. Cenobamate as add-on therapy for drug resistant epilepsies: effectiveness, drug to drug interactions and neuropsychological impact. What have we learned from real word evidence? Front Pharmacol. 2023;14:1239152.","DOI":"10.3389\/fphar.2023.1239152"},{"issue":"3","key":"1178_CR32","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/epi4.12757","volume":"8","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Santos-Carrasco D, Cabezudo-Garc\u00eda P, et al. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an expanded access program. Epilepsia Open. 2023;8(3):918\u201329.","journal-title":"Epilepsia Open."},{"key":"1178_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.seizure.2023.07.026","volume":"111","author":"\u00c1 Beltr\u00e1n-Corbellini","year":"2023","unstructured":"Beltr\u00e1n-Corbellini \u00c1, Romeral-Jim\u00e9nez M, Mayo P, et al. Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study. Seizure. 2023;111:71\u20137.","journal-title":"Seizure."},{"issue":"10","key":"1178_CR34","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.1007\/s00415-024-12510-1","volume":"271","author":"S Lauxmann","year":"2024","unstructured":"Lauxmann S, Heuer D, Heckelmann J, et al. Cenobamate: real-world data from a retrospective multicenter study. J Neurol. 2024;271(10):6596\u2013604.","journal-title":"J Neurol"},{"key":"1178_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18297","author":"I Loushy","year":"2025","unstructured":"Loushy I, Goldstein L, Devlin K, et al. Real-world use of cenobamate in adults: efficacy and predictors of treatment response. Epilepsia. 2025. https:\/\/doi.org\/10.1111\/epi.18297.","journal-title":"Epilepsia"},{"key":"1178_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-025-01166-8","author":"R Roberti","year":"2025","unstructured":"Roberti R, Di Gennaro G, Cianci V, et al. Exploring the effectiveness of adjunctive cenobamate in focal epilepsy: a time-based analysis. CNS Drugs. 2025. https:\/\/doi.org\/10.1007\/s40263-025-01166-8.","journal-title":"CNS Drugs"},{"issue":"3","key":"1178_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40263-025-01158-8","volume":"39","author":"A Strzelczyk","year":"2025","unstructured":"Strzelczyk A, von Podewils F, Hamer HM, et al. Post-marketing experience with cenobamate in the treatment of focal epilepsies: a multicentre cohort study. CNS Drugs. 2025;39(3):321\u201331.","journal-title":"CNS Drugs"},{"key":"1178_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2023.09.006","volume":"112","author":"KL Makridis","year":"2023","unstructured":"Makridis KL, Kaindl AM. Real-world experience with cenobamate: a systematic review and meta-analysis. Seizure. 2023;112:1\u201310.","journal-title":"Seizure."},{"key":"1178_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2022.100533","volume":"18","author":"GS Connor","year":"2022","unstructured":"Connor GS, Williamson A. Effectiveness and safety of adjunctive cenobamate for focal seizures in adults with developmental disability treated in clinical practice. Epilepsy Behav Rep. 2022;18: 100533.","journal-title":"Epilepsy Behav Rep."},{"key":"1178_CR40","doi-asserted-by":"publisher","first-page":"1209487","DOI":"10.3389\/fneur.2023.1209487","volume":"14","author":"AL Friedo","year":"2023","unstructured":"Friedo AL, Greshake B, Makridis KL, et al. Cenobamate significantly improves seizure control in intellectually disabled patients with drug-resistant epilepsy and allows drug load reduction. Front Neurol. 2023;14:1209487.","journal-title":"Front Neurol"},{"key":"1178_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2023.107207","volume":"197","author":"S Stern","year":"2023","unstructured":"Stern S, Weingarten M, Mandapati S, et al. Real-world analysis of retention on cenobamate in patients with epilepsy in the United States. Epilepsy Res. 2023;197: 107207.","journal-title":"Epilepsy Res"},{"issue":"4","key":"1178_CR42","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/epi4.12959","volume":"9","author":"JJ Rodr\u00edguez-Uranga","year":"2024","unstructured":"Rodr\u00edguez-Uranga JJ, Sanchez-Caro JM, Hariramani Ramchanda R. Treatment simplification to optimize cenobamate effectiveness and tolerability: a real-world retrospective study in Spain. Epilepsia Open. 2024;9(4):1345\u201356.","journal-title":"Epilepsia Open."},{"key":"1178_CR43","unstructured":"Pellinen J, Wade C, Stern S, et al. Effectiveness of cenobamate in postsurgical patients: a retrospective claims-based analysis [abstract no. 2.293]. In: American Epilepsy Society Annual Meeting. 2023."},{"key":"1178_CR44","unstructured":"Urban A, Stern S, Wade C, et al. Comparative effectiveness of cenobamate in reducing hospitalizations in patients with focal-onset seizures: a retrospective claims-based analysis [abstract no. 2.294]. In: American Epilepsy Society Annual Meeting. 2023."},{"key":"1178_CR45","unstructured":"Bosak M, Zieli\u0144ski T, K\u015bciuk B, et al. Long-term efficacy of adjunctive cenobamate in patients with refractory epilepsy: a Polish experience [abstract no. 1459]. Epilepsia. 2023;64(Suppl 2):515."},{"key":"1178_CR46","unstructured":"Jord\u00e1n Z, Pet\u0151 N, S\u00e1kovics A, et al. Long-term results with the novel anti-seizure medication, cenobamate, in a single center in Hungary [abstract no. 1606]. Epilepsia. 2023;64(Suppl 2):522-3."},{"issue":"6","key":"1178_CR47","doi-asserted-by":"publisher","first-page":"492","DOI":"10.5603\/pjnns.97121","volume":"57","author":"A Lasek-Bal","year":"2023","unstructured":"Lasek-Bal A, K\u015bciuk B, Zieli\u0144ski T, et al. Long-term cenobamate retention, efficacy, and safety: outcomes from Expanded Access Programme. Neurol Neurochir Pol. 2023;57(6):492\u20136.","journal-title":"Neurol Neurochir Pol"},{"key":"1178_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109605","volume":"151","author":"GL Krauss","year":"2024","unstructured":"Krauss GL, Chung SS, Ferrari L, et al. Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies. Epilepsy Behav. 2024;151: 109605.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"1178_CR49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/ane.13659","volume":"146","author":"BJ Steinhoff","year":"2022","unstructured":"Steinhoff BJ, Ben-Menachem E, Brandt C, et al. Onset of efficacy and adverse events during cenobamate titration period. Acta Neurol Scand. 2022;146(3):265\u201375.","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"1178_CR50","doi-asserted-by":"publisher","first-page":"A60","DOI":"10.1136\/jnnp-2022-ABN.192","volume":"93","author":"I Morales","year":"2022","unstructured":"Morales I, Brodie M, Milanov I, et al. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures. J Neurol Neurosurg Psychiatry. 2022;93(6):A60.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1178_CR51","doi-asserted-by":"crossref","unstructured":"Ferrari L, Rosenfeld W. Effects of cenobamate on weight: post-hoc analyses of global phase 2 and 3 studies [abstract no. P11-1.007]. Neurology. 2023;100(17 Suppl 2).","DOI":"10.1212\/WNL.0000000000201780"},{"issue":"4","key":"1178_CR52","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/cpdd.1077","volume":"11","author":"B Darpo","year":"2022","unstructured":"Darpo B, Sager PT, Xue H, et al. A phase 1 clinical study evaluating the effects of cenobamate on the QT interval. Clin Pharmacol Drug Dev. 2022;11(4):523\u201334.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"4","key":"1178_CR53","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/epi.17935","volume":"65","author":"L Ferrari","year":"2024","unstructured":"Ferrari L, Rosenfeld WE, Kamin M. A global update on cenobamate based on real-world experience in over 100 000 patients. Epilepsia. 2024;65(4):1149\u201350.","journal-title":"Epilepsia"},{"key":"1178_CR54","unstructured":"National Institute for Health and Care Excellence. Epilepsies in children, young people and adults: NICE guideline [NG217]. 2022. https:\/\/www.nice.org.uk\/guidance\/ng217. Accessed 9 Jan 2025."},{"key":"1178_CR55","unstructured":"National Institute for Health and Care Excellence. Cenobamate for treating focal onset seizures in epilepsy: technology appraisal guidance [TA753]. 2021. https:\/\/www.nice.org.uk\/guidance\/ta753. Accessed 9 Jan 2025."},{"key":"1178_CR56","unstructured":"Sociedad Espa\u00f1ola de Neurolog\u00eda. Gu\u00eda de Epilepsia 2022. http:\/\/guiaepilepsia.sen.es\/index.php\/guia. Accessed 7 Mar 2025."},{"issue":"6","key":"1178_CR57","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/j.1528-1167.2010.02952.x","volume":"52","author":"DC Hesdorffer","year":"2011","unstructured":"Hesdorffer DC, Tomson T, Benn E, et al. Combined analysis of risk factors for SUDEP. Epilepsia. 2011;52(6):1150\u20139.","journal-title":"Epilepsia"},{"issue":"2","key":"1178_CR58","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","volume":"82","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs. 2022;82(2):199\u2013218.","journal-title":"Drugs"},{"key":"1178_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108429","volume":"126","author":"M Privitera","year":"2022","unstructured":"Privitera M, Richy FF, Schabert VF. Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures. Epilepsy Behav. 2022;126: 108429.","journal-title":"Epilepsy Behav"},{"key":"1178_CR60","doi-asserted-by":"publisher","first-page":"1307296","DOI":"10.3389\/fneur.2023.1307296","volume":"14","author":"Y Yang","year":"2023","unstructured":"Yang Y, Shangguan Y, Wang X, et al. The efficacy and safety of third-generation antiseizure medications and non-invasive brain stimulation to treat refractory epilepsy: a systematic review and network meta-analysis study. Front Neurol. 2023;14:1307296.","journal-title":"Front Neurol"},{"key":"1178_CR61","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.seizure.2024.04.004","volume":"118","author":"S Mulheron","year":"2024","unstructured":"Mulheron S, Leahy TP, McStravick M, et al. A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: a systematic review and network meta-analysis. Seizure. 2024;118:80\u201390.","journal-title":"Seizure."},{"key":"1178_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109653","volume":"152","author":"J Tong","year":"2024","unstructured":"Tong J, Ji T, Liu T, et al. Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: a systematic review and network meta-analysis. Epilepsy Behav. 2024;152: 109653.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"1178_CR63","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/epi4.12997","volume":"9","author":"H Zhang","year":"2024","unstructured":"Zhang H, Ou Z, Zhang E, et al. Efficacy and safety of add-on antiseizure medications for focal epilepsy: a network meta-analysis. Epilepsia Open. 2024;9(4):1550\u201364.","journal-title":"Epilepsia Open."},{"key":"1178_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102513","volume":"70","author":"Y Chen","year":"2024","unstructured":"Chen Y, Li W, Lu C, et al. Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials. EClinicalMedicine. 2024;70: 102513.","journal-title":"EClinicalMedicine."},{"key":"1178_CR65","doi-asserted-by":"crossref","unstructured":"Perucca E, Bialer M, White HS. New GABA-targeting therapies for the treatment of seizures and epilepsy: I. Role of GABA as a modulator of seizure activity and recently approved medications acting on the GABA system. CNS Drugs. 2023;37(9):755\u201379.","DOI":"10.1007\/s40263-023-01027-2"},{"key":"1178_CR66","doi-asserted-by":"publisher","first-page":"175628642412567","DOI":"10.1177\/17562864241256733","volume":"17","author":"BJ Steinhoff","year":"2024","unstructured":"Steinhoff BJ, Ben-Menachem E, Klein P, et al. Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations. Ther Adv Neurol Disord. 2024;17:17562864241256732.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"1178_CR67","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/epi4.12936","volume":"9","author":"M Carreno","year":"2024","unstructured":"Carreno M, Gil-Nagel A, Serratosa JM, et al. Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures. Epilepsia Open. 2024;9(3):1051\u20138.","journal-title":"Epilepsia Open."},{"issue":"4","key":"1178_CR68","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","volume":"11","author":"MC Smith","year":"2022","unstructured":"Smith MC, Klein P, Krauss GL, et al. Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations. Neurol Ther. 2022;11(4):1705\u201320.","journal-title":"Neurol Ther."},{"key":"1178_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109156","volume":"142","author":"M Osborn","year":"2023","unstructured":"Osborn M, Abou-Khalil B. The cenobamate-clobazam interaction: evidence of synergy in addition to pharmacokinetic interaction. Epilepsy Behav. 2023;142: 109156.","journal-title":"Epilepsy Behav"},{"issue":"6","key":"1178_CR70","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","volume":"35","author":"R Roberti","year":"2021","unstructured":"Roberti R, De Caro C, Iannone LF, et al. Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability. CNS Drugs. 2021;35(6):609\u201318.","journal-title":"CNS Drugs"},{"issue":"3","key":"1178_CR71","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40266-024-01102-3","volume":"41","author":"R O'Dwyer","year":"2024","unstructured":"O\u2019Dwyer R, Stern S, Wade CT, et al. Safety and efficacy of cenobamate for the treatment of focal seizures in older patients: post hoc analysis of a phase III, multicenter, open-label study. Drugs Aging. 2024;41(3):251\u201360.","journal-title":"Drugs Aging"},{"issue":"4","key":"1178_CR72","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/epi.17506","volume":"64","author":"V Laskier","year":"2023","unstructured":"Laskier V, Agyei-Kyeremateng KK, Eddy AE, et al. Cost-effectiveness of cenobamate for focal seizures in people with drug-resistant epilepsy. Epilepsia. 2023;64(4):843\u201356.","journal-title":"Epilepsia"},{"issue":"7","key":"1178_CR73","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/14737167.2022.2107507","volume":"22","author":"MA Calleja","year":"2022","unstructured":"Calleja MA, Navarro A, Serratosa JM, et al. Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain. Expert Rev Pharmacoecon Outcomes Res. 2022;22(7):1127\u201336.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1178_CR74","unstructured":"National Centre for Pharmacoeconomics Ireland. Cost-effectiveness of cenobamate (Ontozry\u00ae) for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products: technical summary. 2022. https:\/\/www.ncpe.ie\/cenobamate-ontozry-hta-id-21025\/. Accessed 14 Jan 2025."},{"key":"1178_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.109054","volume":"139","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Serratosa JM, Toledo M, et al. Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain. Epilepsy Behav. 2023;139: 109054.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1178_CR76","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/13696998.2024.2443338","volume":"28","author":"N Li","year":"2025","unstructured":"Li N, Majoie M, Evers S, et al. Budget impact analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands. J Med Econ. 2025;28(1):114\u201323.","journal-title":"J Med Econ"},{"key":"1178_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173117","volume":"879","author":"R Sharma","year":"2020","unstructured":"Sharma R, Nakamura M, Neupane C, et al. Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;879: 173117.","journal-title":"Eur J Pharmacol"},{"key":"1178_CR78","doi-asserted-by":"crossref","unstructured":"Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: a summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development. Epilepsia. 2020;61(11):2365\u201385.","DOI":"10.1111\/epi.16726"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01178-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01178-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01178-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T08:03:24Z","timestamp":1749801804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01178-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":78,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1178"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01178-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"9 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tina Nie and Sheridan M. Hoy are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}